VANCOUVER, British Columbia, May 9, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced the voting results from its Annual General and Special Meeting of Shareholders held Thursday May 8, 2014 in Vancouver, B.C. Shareholders voted in favor of all items of business, including the election of each of the six director nominees as follows:
|
|
|
Nominee |
Votes For |
% For |
Votes Withheld |
% Withheld |
|
Peggy Phillips |
7,903,418 |
99.79% |
16,513 |
0.21% |
|
Kenneth Galbraith |
7,904,317 |
99.80% |
15,614 |
0.20% |
|
Don Jewell |
7,906,117 |
99.83% |
13,814 |
0.17% |
|
Frank Karbe |
7,904,192 |
99.80% |
15,739 |
0.20% |
|
Daniel Kisner |
7,901,142 |
99.76% |
18,789 |
0.24% |
|
Mark J. Murray |
7,902,367 |
99.78% |
17,564 |
0.22% |
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, B.C.
CONTACT: Investors
Tekmira Investor Relations
Phone: 604-419-3200
Email: ir@tekmira.com
Media
Alan Bayless
Longview Communications Inc.
Phone: 604-694-6035
Email: abayless@longview.ca
